During the past decade, there has been tremendous progress in identifying
novel risk factors and precisely delineating the role of traditional risk
factors associated with coronary heart disease (CHD), with substantial research
advances related to the role of lipoproteins and lipid metabolism. Observational
studies have established the relationship of serum cholesterol and other lipoproteins
with CHD in specific subgroups.1- 3
Clinical trials have demonstrated convincing benefits of cholesterol lowering
for reducing death and myocardial infarction among patients with CHD4,5 as well as beneficial effects of cholesterol
lowering for decreasing the incidence of cardiac events in patients without
established coronary disease.6,7
Accurately synthesizing and appropriately applying this rapidly accumulating
evidence into clinical practice is essential for reducing the morbidity and
mortality associated with coronary disease.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 41
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
For example, ecologic studies such as the Seven Countries Study16 suggested a strong...
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.